Monoclonal antibodies (mAbs) have shown efficacy against SARS-CoV-2 infection in clinical trials. Here the authors model the dose-response relationship between the dose of mAbs and protection from symptomatic SARS-CoV-2 infection. Further, the protection is comparable to that achieved by vaccination.
- Eva Stadler
- Martin T. Burgess
- David S. Khoury